You are here
Become a Clinical Trial Site with Pfizer
Clinical trials depend on the experience of healthcare professionals who have dedicated themselves to clinical research. Pfizer is proud to partner with over 6,000 investigators and site staff to conduct our clinical trials around the world. Whether you’re driven by helping patients, advancing medicine, or both, you could help create the next breakthrough.
2019 Eagle Award Winner
In 2019, the Society for Clinical Research Sites recognized Pfizer with the prestigious Eagle Award. This award is in recognition of the excellence that we can achieve together with dedicated clinical trial partners like you.
Our Areas of Focus
Pfizer develops breakthrough medicines across a wide variety of diseases and therapeutic areas.
Inflammation & Immunology
The Inflammation & Immunology development team is dedicated to bringing potential new treatments to patients affected by chronic inflammatory diseases, including alopecia areata, atopic dermatitis, Crohn’s disease, psoriasis, rheumatoid arthritis and ulcerative colitis.
The Internal Medicine development team advances innovative medicines that address debilitating and devastating medical challenges impacting large patient populations. Development programs in Internal Medicine are currently underway in diabetes, cardiovascular disease, obesity, cachexia and non-alcoholic steatohepatitis (NASH).
The Oncology development team is committed to discovering, investigating, and developing transformative therapies that significantly improve the lives of people with cancer worldwide. Our robust pipeline of novel medicines covers a broad range of cancers. We study these medicines alone and in combination with other treatments to fully explore their ability to change people’s lives.
The Rare Disease development team helps to develop medicines for people around the world who are suffering from serious illnesses with few or no effective treatment options. Areas of focus include gene therapy, cardiomyopathy, Duchenne muscular dystrophy, growth hormone deficiencies, and hemophilia (A and B).
The Vaccines development team includes an ongoing focus on the prevention of pneumococcal disease, including in adults. We are also advancing vaccines for additional deadly adolescent and adult infections including meningococcal disease, respiratory syncytial virus and Guillain-Barré syndrome.
Become a Study Site Partner
If our therapeutic areas of focus align with your areas of interest, email us your contact details, institution or site name and therapeutic areas of interest. Together, breakthroughs are possible.